The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with long-la
- PDF / 969,688 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 85 Downloads / 145 Views
ORIGINAL ARTICLE
The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with longlasting Graves’ hyperthyroidism Vladan Sekulić1 · Milena Rajić1 · Marina Vlajković1 · Slobodan Ilić1 · Miloš Stević1 · Marko Kojić1
Received: 20 June 2017 / Accepted: 3 September 2017 © The Japanese Society of Nuclear Medicine 2017
Abstract Objective The outcome of radioiodine therapy (RIT) in Graves’ hyperthyroidism (GH) mainly depends on radioiodine (131I) uptake and the effective half-life of 131I in the gland. Studies have shown that lithium carbonate ( LiCO3) enhances the 131I half-life and increases the applied thyroid radiation dose without affecting the thyroid 131I uptake. We investigated the effect of short-term treatment with LiCO3 on the outcome of RIT in patients with long-lasting GH, its influence on the thyroid hormones levels 7 days after RIT, and possible side effects. Methods Study prospectively included 30 patients treated with LiCO3 and 131I (RI-Li group) and 30 patients only with 131 I (RI group). Treatment with LiCO3 (900 mg/day) started 1 day before RIT and continued 6 days after. Anti-thyroid drugs withdrawal was 7 days before RIT. Patients were followed up for 12 months. We defined a success of RIT as euthyroidism or hypothyroidism, and a failure as persistent hyperthyroidism. Results In RI-Li group, a serum level of Li was 0.571 ± 0.156 mmol/l before RIT. Serum levels of T T4 and FT4 increased while TSH decreased only in RI group 7 days after RIT. No toxic effects were noticed during LiCO3 treatment. After 12 months, a success of RIT was 73.3% in RI and 90.0% in RI-Li group (P
Data Loading...
